Loading
In AETHERA, a year of the CD30 ADC after transplant halved relapse risk in high-risk patients.
AETHERA, trial NCT01100502 sponsored by Seagen and published in the Lancet in 2015, showed that a year of the CD30 antibody-drug conjugate brentuximab vedotin after autologous transplant halved the risk of relapse in high-risk Hodgkin lymphoma. It randomised 329 patients to brentuximab consolidation or placebo and met its primary progression-free survival endpoint with a large effect, while overall survival did not differ because of crossover, leading to approval in August 2015 as post-transplant consolidation. OnCo links it to Hodgkin lymphoma, autologous transplant and brentuximab vedotin. Now that brentuximab and PD-1 blockade are used before transplant, whether consolidation still adds anything is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Brentuximab vedotin, Relapsed and refractory classical Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Brentuximab vedotin, Hodgkin lymphoma.
Shares Brentuximab vedotin, Hodgkin lymphoma.